Inhibition of FOXO1 through drugs like AS1842856 and trifluoperazine has shown promise in reducing blood sugar [75], impairing autophagy in diabetes [76], preventing left ventricular atrophy [77], and overcoming chemoresistance in breast cancer [78]. This evidence concerns the gene FOXO1 and diabetes mellitus.